Relative effectiveness of bivalent Original/Omicron BA.4-5 mRNA vaccine in preventing severe COVID-19 in persons 60 years and above during SARS-CoV-2 Omicron XBB.1.5 and other XBB sublineages circulation, Italy, April to June 2023-Reference-Cited by-同舟云学术

Relative effectiveness of bivalent Original/Omicron BA.4-5 mRNA vaccine in preventing severe COVID-19 in persons 60 years and above during SARS-CoV-2 Omicron XBB.1.5 and other XBB sublineages circulation, Italy, April to June 2023

Published:2023-08-10 Issue:32 Volume:28 Page:
ISSN:1560-7917
Container-title:Eurosurveillance
language:en
Short-container-title:

Author:

Fabiani Massimo¹,Mateo-Urdiales Alberto¹,Sacco Chiara¹,Rota Maria Cristina¹,Fotakis Emmanouil Alexandros²¹,Petrone Daniele¹,Del Manso Martina¹,Siddu Andrea³,Stefanelli Paola¹,Bella Antonino¹,Riccardo Flavia¹,Rezza Giovanni³,Palamara Anna Teresa¹,Brusaferro Silvio⁴,Pezzotti Patrizio¹,

Affiliation:

1. Department of Infectious Diseases, Istituto Superiore di Sanità, Rome, Italy

2. European Programme on Intervention Epidemiology Training (EPIET), European Centre for Disease Prevention and Control, Stockholm, Sweden

3. General Directorate of Prevention, Italian Ministry of Health, Rome, Italy

4. Office of the President, Istituto Superiore di Sanità, Rome, Italy

Abstract

During predominant circulation of SARS-CoV-2 Omicron XBB.1.5 and other XBB sublineages (April–June 2023), we found that a second or third booster of Comirnaty bivalent Original/Omicron BA.4-5 mRNA vaccine, versus a first booster received at least 120 days earlier, was effective in preventing severe COVID-19 for more than 6 months post-administration in persons 60 years and above. In view of autumn 2023 vaccination campaigns, use of bivalent Original/Omicron BA.4-5 mRNA vaccines might be warranted until monovalent COVID-19 vaccines targeting Omicron XBB.1 sublineages become available.

Publisher

European Centre for Disease Control and Prevention (ECDC)

Subject

Virology,Public Health, Environmental and Occupational Health,Epidemiology

Reference21 articles.

1. World Health Organization (WHO). Statement on the antigens composition of COVID-19 vaccines. Geneva: WHO; 2023. Available from: https://www.who.int/news/item/18-05-2023-statement-on-the-antigen-composition-of-covid-19-vaccines

2. European Centre for Disease Prevention and Control (ECDC), European Medicines Agency (EMA). ECDC-EMA statement on updating COVID-19 vaccines composition for new SARS-CoV-2 virus variants.Stockholm and Amsterdam: ECDC and EMA. [Accessed: 17 Jul 2023]. Available from: https://www.ema.europa.eu/en/documents/other/ecdc-ema-statement-updating-covid-19-vaccines-composition-new-sars-cov-2-virus-variants_en.pdf

3. World Health Organization (WHO). Weekly Epidemiological Update on COVID-19 – 6 July 2023. Geneva: WHO. [Accessed: 17 Jul 2023]. Available from: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---6-july-2023

4. Early estimates of bivalent mRNA booster dose vaccine effectiveness in preventing symptomatic SARS-CoV-2 infection attributable to Omicron BA.5- and XBB/XBB.1.5-related sublineages among immunocompetent adults - increasing community access to testing program, United States, December 2022-January 2023.;Link-Gelles;MMWR Morb Mortal Wkly Rep,2023

5. Durability of bivalent boosters against Omicron subvariants.;Lin;N Engl J Med,2023

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Relative effectiveness of bivalent boosters against severe COVID-19 outcomes among people aged ≥ 65 years in Finland, September 2022 to August 2023;Eurosurveillance;2024-09-12

2. COVID-19 Vaccine Effectiveness in Autumn and Winter 2022 to 2023 Among Older Europeans;JAMA Network Open;2024-07-01

3. Neutralization of EG.5, EG.5.1, BA.2.86, and JN.1 by antisera from dimeric receptor-binding domain subunit vaccines and 41 human monoclonal antibodies;Med;2024-05

4. A systematic review and meta-analysis on the effectiveness of bivalent mRNA booster vaccines against Omicron variants;Vaccine;2024-05

5. Estimating All-Cause Deaths Averted in the First Two Years of the COVID-19 Vaccination Campaign in Italy;Vaccines;2024-04-13